Huaheng Bio Passes HKEX Main Board Listing Hearing, Aims to Be "Hong Kong’s First Synthetic Biology Stock"

NewTimeSpace · 2026/06/23 09:02 · By Zehong Cheng

NewTimeSpace News: Anhui Huaheng Biotechnology Co., Ltd. passed the Main Board listing hearing of the Hong Kong Stock Exchange on 22 June, striving to become "Hong Kong’s First Synthetic Biology Stock". Huatai International serves as the sole sponsor. According to Frost & Sullivan, measured by revenue in 2025, the Company ranks first globally in market share for both L-Alanine and L-Valine.

NewTimeSpace News: As disclosed by the Hong Kong Stock Exchange, Anhui Huaheng Biotechnology Co., Ltd. passed the Main Board listing hearing of the Hong Kong Stock Exchange on 22 June 2026, targeting to be "Hong Kong’s First Synthetic Biology Stock", with Huatai International appointed as the sole sponsor.

Huaheng Biotechnology is a global player in synthetic biology technology, focusing on the R&D, large-scale production and commercialization of bio-based products relying on bio-manufacturing technology. According to Frost & Sullivan measured by 2025 revenue, the Company holds the world’s top market share for both L-Alanine and L-Valine. The global bio-based product market expanded from USD 22.8 billion in 2020 to USD 48.1 billion in 2025, and is projected to reach USD 78.6 billion by 2030 and USD 103.5 billion by 2035.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

Huaheng Bio IPO pass the listing hearing